PHARMACEUTICAL giant Pfizer
has won its battle to retain the
validity of its patent on its US$4.6b
neuropathic pain therapy Lyrica
(pregabalin) in the US Court of
Appeals for the Federal Circuit in
Washington this week.
As well as neuropathic pain such
as that that from shingles and
fibromyalgia, Lyrica is also used to
treat epilepsy and hot flashes and
according to a Bloomberg report,
contributes around 9% of Pfizer’s
total revenue.
Four companies were involved in
the patent challenge: Teva, Actavis,
Lupin and Sun Pharmaceuticals.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Mar 14
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.